VivoSeq
Other

Dysphagia

22

Pipeline Programs↗

12

Active Trials↗

15

Companies Involved↗

Dysphagia is an emerging landscape with 22 programs across 15 companies. The most active players are CD Pharma India Pvt. Ltd., Teva, Takeda. 1 therapy is approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

22/100

Mech. Concentration

21/100

Completion Rate

76/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

CD Pharma India Pvt. Ltd.

1 program

Phase 1Teva logo

Teva

1 program

Phase 1Takeda logo

Takeda

1 program

Phase 2K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 3R

Revance Therapeutics, Inc.

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

40

clinical trials

Completed19 · 48%
Recruiting7 · 18%
Not yet recruiting3 · 8%
Withdrawn3 · 8%
Terminated3 · 8%
Unknown status3 · 8%
Other2 · 5%

Clinical Trials

Trial Activity

40 trials

Novel Treatment of Radiation Associated Dysphagia With Statins
Recruiting·PPeter MacCallum Cancer Centre, Australia·Phase 2·NCT07217938·48 enrolled
Effect of Specific Mode Electroacupuncture Stimulation Combined with NGF on Dysphagia After Ischaemic Stroke: a Pilot Randomized Controlled Trial
Recruiting·TThe Third Affiliated hospital of Zhejiang Chinese Medical University·Phase 4·NCT06737549·144 enrolled
Corticosteroids for Post-Extubation Dysphagia
Recruiting·UUniversity of Colorado, Denver·Phase 2·NCT06670521·80 enrolled
Use of the Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans With Dysphagia in Mali and the United States
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT07027826·70 enrolled
Phagenyx® Registry Study: Evaluating Swallowing Therapy Outcomes and Recovery in the U.S.
Recruiting·PPhagenesis Ltd.·N/A·NCT06866418·600 enrolled
Effect of an Oral Neuromuscular Training Device on Dysphagia: an Assessor-blinded Randomized Controlled Trial
Recruiting·UUniversity of Aarhus·Preclinical·NCT07451028·100 enrolled
Efficacy and Safety of Onabotulinum Toxin A (Botox) Injections in the Upper Esophageal Sphincter for the Treatment of Pharyngo-esophageal Dysphagia Due to Cricopharyngeal Dysfunction- A Randomized Double Blinded Placebo Controlled Trial
Recruiting·AAll India Institute of Medical Sciences·Preclinical·NCT04695600·100 enrolled
Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia
Active, not recruiting·—·Phase 1·NCT02838316·18 enrolled
Autologous Muscle Derived Cells for Treatment of Tongue Dysphagia
Active, not recruiting·UUniversity of California, Davis·Phase 1/2·NCT05421689·66 enrolled
The Effectiveness of Stellate Ganglion Block in Managing Dysphagia in Patients With Medullary Infarction
Not yet recruiting·—·N/A·NCT06301698·80 enrolled
Efficacy of Omaveloxolone Treatment for Dysphagia in French Patients With Friedreich's Ataxia
Not yet recruiting·—·N/A·NCT07013292·40 enrolled
Pharyngeal High Resolution Manometry Standardization of Metrics
Not yet recruiting·UUniversity of Wisconsin, Madison·Preclinical·NCT07475091·25 enrolled
Identifying and Treating Arousal Related Deficits in Neglect and Dysphagia
Completed·UUniversity of Arkansas·Phase 2·NCT01085903·28 enrolled
Effect of Local Intraoperative Steroid on Dysphagia After ACDF
Completed·RRush University Medical Center·Phase 3·NCT03311425·140 enrolled
Buspirone for Functional Dysphagia
Completed·TThe Cleveland Clinic·N/A·NCT02674412·10 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)